Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

The Effect of Walking in Kidney Transplant Patients

6 de agosto de 2021 actualizado por: FATMA DEMIR KORKMAZ, Ege University

The Effect of Pedometer Assisted Walking on Physical Activity Level and Metabolic Parameters in Patients With Renal Transplantation

Cardiovascular diseases are among the most common causes of death in kidney transplant patients. Physical activity is of great importance in preventing cardiovascular diseases after transplantation. Although regular physical activity is recommended in international guidelines to prevent post-transplant mortality and morbidity in kidney transplant patients, studies have shown that patients do not follow regular physical activity instructions.The aim of our project is to examine the effect of pedometer-assisted physical activity on metabolic parameters after kidney transplantation.

Descripción general del estudio

Estado

Reclutamiento

Intervención / Tratamiento

Descripción detallada

Patients with kidney transplant surgery will be randomized to the intervention (n: 34) and control groups (n: 34), respectively, according to the transplant surgery date. Intervention and Control groups will be given the same training on the importance of physical activity during discharge training. The pedometer will be given to the intervention group to evaluate the activity level, and it will be said that their goal is to take 2000 steps in 20 minutes a day after discharge. Patients will be asked to carry the pedometer during physical activity, and to write down the number of steps they take in 20 minutes on the form given to them for 90 days. Patients in the control group will only be advised to do physical activity every day and will be asked to record the minutes of physical activity they do for 90 days. Metabolic parameters of the patients in the intervention and control groups will be examined at the end of the 4th and 12th months. These parameters are blood pressure, body mass index, complete blood count (hemoglobin, leukocyte, thrombocyte), blood glucose, sodium, potassium, calcium, liver enzymes, serum creatinine, total and indirect bilirubin, albumin and total cholesterol levels.

Tipo de estudio

Intervencionista

Inscripción (Anticipado)

68

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Fatma DEMIR KORKMAZ, Professor
  • Número de teléfono: +902323115506
  • Correo electrónico: fatma.demir@ege.edu.tr

Copia de seguridad de contactos de estudio

Ubicaciones de estudio

      • Izmir, Pavo, 35040
        • Reclutamiento
        • Ege university
        • Contacto:
          • Fatma DEMIR KORKMAZ, Professor
          • Número de teléfono: +902323115506
          • Correo electrónico: fatma.demir@ege.edu.tr
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 65 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria: • Over the age of 18 and under the age of 65,

  • Kidney transplantation at the center where the study was conducted between the research dates,
  • There is no activity restriction recommendation by the physician,
  • Patients who agree to participate in the study.

Exclusion Criteria:

  • Multiple organ transplantation at the same time,
  • Death or graft loss/rejection in the hospital before discharge,
  • Patients with physical activity restrictions by the physician,
  • Patients who are re-hospitalized within the first 3 months after discharge

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Prevención
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Using a pedometer
The pedometer will be given to the intervention group to evaluate the activity level and to encourage a walk , it will be said that their goal is to take 2000 steps in 20 minutes a day after discharge. Patients will be asked to carry the pedometer during physical activity, and to write down the number of steps they take in 20 minutes on the form given to them for 90 days.
2000 steps per day in 20 minutes for 90 days, guided by a pedometer after a kidney transplantation
Sin intervención: Not using a pedometer
The control group will not be given a pedometer.Patients in the control group will only be instructed to do physical activity every day and will be asked to record the minutes of physical activity they do for 90 days.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Blood Pressure
Periodo de tiempo: Change from Baseline Blood Pressure at 4 months after discharge
mmHg
Change from Baseline Blood Pressure at 4 months after discharge
Blood Pressure
Periodo de tiempo: Change from Baseline Blood Pressure at 12 months after discharge
mmHg
Change from Baseline Blood Pressure at 12 months after discharge
Body Mass Index (BMI)
Periodo de tiempo: Change from Baseline BMI at 4 months after discharge
BMI is weight in kilograms divided by height in meters squared. Formula: weight (kg) / [height (m)]2
Change from Baseline BMI at 4 months after discharge
Body Mass Index (BMI)
Periodo de tiempo: Change from Baseline BMI at 12 months after discharge
BMI is weight in kilograms divided by height in meters squared. Formula: weight (kg) / [height (m)]2
Change from Baseline BMI at 12 months after discharge
Hemoglobin
Periodo de tiempo: Change from Baseline Hemoglobin at 4 months after discharge
g/dL
Change from Baseline Hemoglobin at 4 months after discharge
Hemoglobin
Periodo de tiempo: Change from Baseline Hemoglobin at 12 months after discharge
g/dL
Change from Baseline Hemoglobin at 12 months after discharge
Leukocyte
Periodo de tiempo: Change from Baseline Leukocyte at 4 months after discharge
10^3/µL
Change from Baseline Leukocyte at 4 months after discharge
Leukocyte
Periodo de tiempo: Change from Baseline Leukocyte at 12 months after discharge
10^3/µL
Change from Baseline Leukocyte at 12 months after discharge
Thrombocyte
Periodo de tiempo: Change from Baseline Thrombocyte at 4 months after discharge
10^3/µL
Change from Baseline Thrombocyte at 4 months after discharge
Thrombocyte
Periodo de tiempo: Change from Baseline Thrombocyte at 12 months after discharge
10^3/µL
Change from Baseline Thrombocyte at 12 months after discharge
Blood Glucose
Periodo de tiempo: Change from Baseline Blood Glucose at 4 months after discharge
mg/dL
Change from Baseline Blood Glucose at 4 months after discharge
Blood Glucose
Periodo de tiempo: Change from Baseline Blood Glucose at 12 months after discharge
mg/dL
Change from Baseline Blood Glucose at 12 months after discharge
Sodium
Periodo de tiempo: Change from Baseline Sodium at 4 months after discharge
mEq/L
Change from Baseline Sodium at 4 months after discharge
Sodium
Periodo de tiempo: Change from Baseline Sodium at 12 months after discharge
mEq/L
Change from Baseline Sodium at 12 months after discharge
Potassium
Periodo de tiempo: Change from Baseline Sodium at 4 months after discharge
mEq/L
Change from Baseline Sodium at 4 months after discharge
Potassium
Periodo de tiempo: Change from Baseline Sodium at 12 months after discharge
mEq/L
Change from Baseline Sodium at 12 months after discharge
Calcium
Periodo de tiempo: Change from Baseline Sodium at 4 months after discharge
mEq/L
Change from Baseline Sodium at 4 months after discharge
Calcium
Periodo de tiempo: Change from Baseline Sodium at 12 months after discharge
mEq/L
Change from Baseline Sodium at 12 months after discharge
Serum Creatinine
Periodo de tiempo: Change from Baseline Sodium at 4 months after discharge
mg/dL
Change from Baseline Sodium at 4 months after discharge
Serum Creatinine
Periodo de tiempo: Change from Baseline Sodium at 12 months after discharge
mg/dL
Change from Baseline Sodium at 12 months after discharge
Total Bilirubin
Periodo de tiempo: Change from Baseline Sodium at 4 months after discharge
mg/dL
Change from Baseline Sodium at 4 months after discharge
Total Bilirubin
Periodo de tiempo: Change from Baseline Sodium at 12 months after discharge
mg/dL
Change from Baseline Sodium at 12 months after discharge
Indirect Bilirubin
Periodo de tiempo: Change from Baseline Sodium at 4 months after discharge
mg/dL
Change from Baseline Sodium at 4 months after discharge
Indirect Bilirubin
Periodo de tiempo: Change from Baseline Sodium at 12 months after discharge
mg/dL
Change from Baseline Sodium at 12 months after discharge
High-density lipoprotein (HDL) cholesterol
Periodo de tiempo: Change from Baseline Sodium at 4 months after discharge
mg/dL
Change from Baseline Sodium at 4 months after discharge
High-density lipoprotein (HDL) cholesterol
Periodo de tiempo: Change from Baseline Sodium at 12 months after discharge
mg/dL
Change from Baseline Sodium at 12 months after discharge
Low-density lipoprotein (LDL) cholesterol
Periodo de tiempo: Change from Baseline Sodium at 4 months after discharge
mg/dL
Change from Baseline Sodium at 4 months after discharge
Low-density lipoprotein (LDL) cholesterol
Periodo de tiempo: Change from Baseline Sodium at 12 months after discharge
mg/dL
Change from Baseline Sodium at 12 months after discharge
Aspartate Aminotransferase
Periodo de tiempo: Change from Baseline Sodium at 4 months after discharge
U/L
Change from Baseline Sodium at 4 months after discharge
Aspartate Aminotransferase
Periodo de tiempo: Change from Baseline Sodium at 12 months after discharge
U/L
Change from Baseline Sodium at 12 months after discharge
Alanine aminotransferase
Periodo de tiempo: Change from Baseline Sodium at 4 months after discharge
U/L
Change from Baseline Sodium at 4 months after discharge
Alanine aminotransferase
Periodo de tiempo: Change from Baseline Sodium at 12 months after discharge
U/L
Change from Baseline Sodium at 12 months after discharge
Alkaline Phosphatase
Periodo de tiempo: Change from Baseline Sodium at 4 months after discharge
U/L
Change from Baseline Sodium at 4 months after discharge
Alkaline Phosphatase
Periodo de tiempo: Change from Baseline Sodium at 12 months after discharge
U/L
Change from Baseline Sodium at 12 months after discharge
Triglyceride
Periodo de tiempo: Change from Baseline Sodium at 4 months after discharge
mg/dL
Change from Baseline Sodium at 4 months after discharge
Triglyceride
Periodo de tiempo: Change from Baseline Sodium at 12 months after discharge
mg/dL
Change from Baseline Sodium at 12 months after discharge
Total Cholesterol
Periodo de tiempo: Change from Baseline Sodium at 4 months after discharge
mg/dL
Change from Baseline Sodium at 4 months after discharge
Total Cholesterol
Periodo de tiempo: Change from Baseline Sodium at 12 months after discharge
mg/dL
Change from Baseline Sodium at 12 months after discharge
Albumin
Periodo de tiempo: Change from Baseline Sodium at 4 months after discharge
g/dL
Change from Baseline Sodium at 4 months after discharge
Albumin
Periodo de tiempo: Change from Baseline Sodium at 12 months after discharge
g/dL
Change from Baseline Sodium at 12 months after discharge
glucose in urine
Periodo de tiempo: Change from Baseline Sodium at 4 months after discharge
mg/dL
Change from Baseline Sodium at 4 months after discharge
glucose in urine
Periodo de tiempo: Change from Baseline Sodium at 12 months after discharge
mg/dL
Change from Baseline Sodium at 12 months after discharge

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Fatma DEMIR KORKMAZ, Professor, Ege University Faculty of Nursing 35000, Izmir, Turkey

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

19 de noviembre de 2020

Finalización primaria (Anticipado)

1 de noviembre de 2022

Finalización del estudio (Anticipado)

1 de noviembre de 2022

Fechas de registro del estudio

Enviado por primera vez

30 de marzo de 2021

Primero enviado que cumplió con los criterios de control de calidad

6 de agosto de 2021

Publicado por primera vez (Actual)

12 de agosto de 2021

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

12 de agosto de 2021

Última actualización enviada que cumplió con los criterios de control de calidad

6 de agosto de 2021

Última verificación

1 de agosto de 2021

Más información

Términos relacionados con este estudio

Términos MeSH relevantes adicionales

Otros números de identificación del estudio

  • fatma.demir1

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir